30,450 Shares in Zai Lab Limited (NASDAQ:ZLAB) Bought by DCF Advisers LLC

DCF Advisers LLC acquired a new stake in shares of Zai Lab Limited (NASDAQ:ZLAB) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 30,450 shares of the company’s stock, valued at approximately $528,000.

Several other hedge funds and other institutional investors have also made changes to their positions in ZLAB. XTX Topco Ltd grew its stake in shares of Zai Lab by 19.2% during the second quarter. XTX Topco Ltd now owns 29,283 shares of the company’s stock valued at $507,000 after buying an additional 4,710 shares during the last quarter. Renaissance Technologies LLC grew its position in Zai Lab by 91.9% in the 2nd quarter. Renaissance Technologies LLC now owns 28,214 shares of the company’s stock valued at $489,000 after acquiring an additional 13,514 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in Zai Lab in the second quarter worth $270,000. TD Asset Management Inc lifted its position in shares of Zai Lab by 1.4% during the second quarter. TD Asset Management Inc now owns 221,970 shares of the company’s stock worth $3,847,000 after purchasing an additional 3,000 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its position in shares of Zai Lab by 96.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 124,096 shares of the company’s stock worth $2,151,000 after purchasing an additional 60,927 shares during the last quarter. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Insiders Place Their Bets

In related news, insider Harald Reinhart sold 7,431 shares of the stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $17.90, for a total value of $133,014.90. Following the completion of the transaction, the insider now directly owns 62,619 shares of the company’s stock, valued at approximately $1,120,880.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Zai Lab news, CEO Ying Du sold 23,939 shares of the business’s stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $17.90, for a total transaction of $428,508.10. Following the sale, the chief executive officer now owns 1,142,833 shares in the company, valued at approximately $20,456,710.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Harald Reinhart sold 7,431 shares of the firm’s stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $17.90, for a total value of $133,014.90. Following the completion of the transaction, the insider now owns 62,619 shares of the company’s stock, valued at $1,120,880.10. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 55,286 shares of company stock valued at $975,291. 5.23% of the stock is currently owned by corporate insiders.

Zai Lab Stock Performance

NASDAQ ZLAB opened at $21.09 on Friday. Zai Lab Limited has a one year low of $13.48 and a one year high of $31.22. The company has a market capitalization of $2.10 billion, a price-to-earnings ratio of -6.04 and a beta of 1.07. The company’s 50-day simple moving average is $18.74 and its two-hundred day simple moving average is $18.05.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.16). Zai Lab had a negative net margin of 92.44% and a negative return on equity of 37.96%. The company had revenue of $100.50 million for the quarter, compared to the consensus estimate of $94.46 million. Equities analysts expect that Zai Lab Limited will post -2.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Zai Lab in a research report on Wednesday, August 7th. JPMorgan Chase & Co. decreased their price target on shares of Zai Lab from $43.00 to $38.00 and set an “overweight” rating for the company in a research note on Friday, July 12th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $58.97.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.